Twist Bioscience (NASDAQ:TWST) CAO Sells 1,482 Shares of Company Stock

05 Oct 2026, 17:09 by Scott Moore · The Cerbat Gem

Twist Bioscience Corporation (NASDAQ:TWST – Get Free Report) CAO Robert Werner sold 1,482 shares of the company’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $188.88, for a total transaction of $279,920.16. Following the transaction, the chief accounting officer owned 42,917 shares of the company’s stock, valued at $8,106,162.96. This trade represents a 3.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Twist Bioscience Price Performance

TWST stock traded up $16.33 during midday trading on Monday, reaching $205.00. 3,203,579 shares of the stock were exchanged, compared to its average volume of 1,622,926. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $207.90. The company has a fifty day moving average price of $136.40 and a 200 day moving average price of $92.42. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. The stock has a market capitalization of $12.86 billion, a PE ratio of -92.34 and a beta of 2.19.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The firm had revenue of $118.38 million for the quarter, compared to analyst estimates of $114.55 million. During the same period in the previous year, the business posted $0.33 earnings per share. The business’s revenue for the quarter was up 23.2% compared to the same quarter last year. As a group, analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on TWST shares. Evercore cut shares of Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price target for the company. in a research report on Monday, July 6th. BWS Financial reaffirmed a “sell” rating and set a $45.00 price target on shares of Twist Bioscience in a research note on Friday, September 18th. UBS Group assumed coverage on shares of Twist Bioscience in a report on Wednesday, September 9th. They set a “neutral” rating and a $144.00 price target on the stock. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 3rd. Finally, Canaccord Genuity Group increased their price objective on Twist Bioscience from $90.00 to $120.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $115.27.

View Our Latest Report on TWST

Key Twist Bioscience News

Here are the key news stories impacting Twist Bioscience this week:

Positive Sentiment: Twist Bioscience reported approximately 23% year-over-year revenue growth in its latest quarter, reinforcing the company’s expansion narrative and helping support bullish sentiment. Twist Bioscience stock reports 23 percent revenue growth
Positive Sentiment: Leerink raised its price target for TWST from $120 to $160, signaling improved analyst expectations. Although the revised target remains below the recent share price, the increase may have added to buying momentum. Leerink raises target for Twist Bioscience stock
Positive Sentiment: The stock reached a new 52-week high, reflecting strong momentum and investor demand. TWST has benefited from enthusiasm around biotechnology and synthetic-DNA markets, as well as attention from actively managed biotech funds. Twist Bioscience reaches new 52-week high
Neutral Sentiment: CEO Emily Leproust, CFO Adam Laponis, CAO Robert Werner, SVP Paula Green and insider Dennis Cho sold shares primarily to cover tax withholding tied to vested equity awards. The transactions totaled roughly $14.3 million, but the CEO’s sales were conducted under a pre-arranged Rule 10b5-1 plan, reducing their usefulness as a signal of deteriorating business prospects. Twist Bioscience insider transaction filing
Negative Sentiment: Valuation and profitability remain risks: the company continues to report net losses, and its latest quarterly earnings per share missed estimates despite beating revenue expectations. The sharp rally also leaves the stock well above Leerink’s revised target, increasing the potential for volatility or profit-taking.

Institutional Investors Weigh In On Twist Bioscience

Several large investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in Twist Bioscience in the second quarter worth approximately $600,191,000. William Blair Investment Management LLC bought a new position in shares of Twist Bioscience during the 2nd quarter worth approximately $223,722,000. Bank of America Corp DE bought a new position in shares of Twist Bioscience during the 2nd quarter worth approximately $94,922,000. Allspring Global Investments Holdings LLC acquired a new stake in shares of Twist Bioscience during the 1st quarter worth approximately $22,563,000. Finally, BNP Paribas Financial Markets grew its position in shares of Twist Bioscience by 242.2% during the 4th quarter. BNP Paribas Financial Markets now owns 415,609 shares of the company’s stock worth $13,183,000 after buying an additional 294,144 shares during the period.

Twist Bioscience Company Profile

(Get Free Report)

Twist Bioscience Corporation (NASDAQ:TWST) is a biotechnology company that develops and manufactures synthetic DNA using a silicon-based production platform. Its technology is designed to enable the precise, high-throughput synthesis of DNA at smaller scale and with potentially lower material consumption than traditional methods.